Search Results
Your search for Blood matches 4628 pages
Showing 3251 - 3300DigniCap Scalp Cooling System Now Available for Women With Breast Cancer at 10 U.S. Cancer Treatment Centers
Dignitana Inc. announced today that the DigniCap scalp cooling system, which was cleared by the U.S. Food and Drug Administration (FDA) in December 2015 to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, is now available at 10 cancer treatment...
Meta-analysis of Gene-Expression Datasets Identifies Novel Five-Gene Pancreatic Cancer Classifier
Pancreatic cancer is often diagnosed at a late stage, when curative treatment is no longer possible. A team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) identified and validated an accurate five-gene classifier for discriminating early pancreatic cancer from nonmalignant...
Microneedle Patch Delivers Localized Anti–PD-1 Antibody Immunotherapy to Melanoma in Preclinical Models
Biomedical engineering researchers at North Carolina State University (NC State) and the University of North Carolina at Chapel Hill (UNC Chapel Hill) have developed a technique that uses a patch embedded with microneedles to deliver cancer immunotherapy treatment directly to the site of melanoma....
Minimal Residual Disease in AML: Worth Looking?
As summarized in this issue of The ASCO Post, Ivey and colleagues demonstrated that assessing for NPM1-mutated gene transcripts by reverse-transcriptase quantitative polymerase chain reaction assay is a feasible approach for measuring minimal residual disease after acute myeloid leukemia (AML)...
Fecal Immunochemical Test Highly Sensitive and Effective When Used for Colorectal Cancer Annual Screening Programs
Annual screening with the fecal immunochemical test is highly sensitive for detecting colorectal cancer and “is feasible and effective for population-level colorectal cancer screening,” according to a large-scale retrospective cohort study assessing this test over four rounds of annual screening....
I Never Forget I Have Cancer
I have a history of fibrocystic breasts, which required biopsies to make certain the cysts were benign, and for years they were. But in 2009, my mammogram screening picked up a suspicious lump in my right breast, which turned out to be stage III estrogen receptor–positive/progesterone...
A Drop of Blood
I was a third-year internal medicine resident, rotating through the oncology service, when I was asked to perform my first circumcision. My team was rounding on Tom, a 52-year-old gentleman currently receiving third-line treatment for metastatic esophageal cancer; we were discussing at length his...
Actively Recruiting Clinical Trials Investigating Late Effects in Childhood Cancer Survivors
PILOT Study Title: Feasibility of Assessing Blood Pressure Remotely in Childhood Cancer Survivors (Pilot Study-Survivor) Study Type: Interventional/randomized/parallel assignment Study Sponsor and Collaborators: St. Jude Children’s Research Hospital Purpose: To evaluate a high blood pressure...
PARP Inhibitor Olaparib Produces High Response Rate in Metastatic Prostate Cancer With DNA-Repair Defects
In the TOPARP-A phase II trial reported in The New England Journal of Medicine, Joaquin Mateo, MD, of the Institute of Cancer Research and The Royal Marsden in London, and colleagues, found that the PARP inhibitor olaparib (Lynparza) produced a high response rate in patients with previously treated ...
Minimal Residual Disease Identified by NPM1 Mutation Is a Powerful Marker for Poorer Outcome in Standard-Risk AML
In a study reported in The New England Journal of Medicine, Adam Ivey, MSc, from Guy’s Hospital, London, and colleagues found that a leukemia-specific marker consisting of mutation in the gene encoding nucleophosmin (NPM1) can be used to identify minimal residual disease in peripheral blood in...
How Rehabilitation Services Provide Benefit for Patients With Spinal Metastases
The benefits of rehabilitation in traumatic spinal injuries are well established. Recently, studies have shown similarly positive results in cancer-related spinal injuries, indicating that rehabilitation can play a complementary role in the care management of this patient population....
Modified CAR T Cells Overcome Immune Suppression, Effective Against Solid Tumors in Preclinical Models
Adding a genetically engineered “switch receptor” to second-generation CAR T cells blocked PD-1–mediated immune suppression, and made the immunotherapy effective against solid tumors in preclinical models, according to a study published by Liu et al in Cancer Research....
Geriatric Assessment of Transplant-Ineligible Older Adults With Multiple Myeloma: A Novel Approach in the Era of Novel Agents
Myeloma is a disease of aging, with a median age at diagnosis in the United States of 69 years.1 As the population ages, forecasts estimate that, within 20 years, 3 of every 4 people diagnosed with multiple myeloma in the United States will be between the ages of 64 and 84 years.2 In anticipation...
2016 ASH-AMFDP Scholars to Study Malaria, Immunotherapy for Hematologic Malignancies
The American Society of Hematology (ASH) is pleased to announce that Natasha Archer, MD, MPH, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Rayne Rouce, MD, of Baylor College of Medicine, have been selected to participate in the American Society of Hematology-Harold Amos...
Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
On February 26, 2016, obinutuzumab (Gazyva) was approved for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for treatment of patients with follicular lymphoma who have relapsed after or are refractory to a rituximab (Rituxan)-containing regimen.1,2...
Palbociclib Combined With Fulvestrant in Advanced Breast Cancer Progressing After Endocrine Therapy
On February 19, 2016, palbociclib (Ibrance) was approved for use in combination with fulvestrant (Faslodex) for treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.1,2 In February 2015, palbociclib in...
Cancer Survivorship Research: Learning From the Past to Improve Future Outcomes
Soon after effective therapies for some childhood malignancies were first identified, early leaders in our field had concerns about what would happen to surviving patients as they aged. In 1975, Giulio D’Angio, MD, one of the founders of modern pediatric radiation oncology, presciently called for...
Robert Seeger, MD, Awarded Lifetime Achievement Award From Pediatric Blood and Marrow Transplant Consortium
Robert Seeger, MD, Division Head for Basic and Translational Research of the Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles (CHLA), has been selected for the 2016 Lifetime Achievement Award from the Pediatric Blood and Marrow Transplant Consortium (PBMTC). As the eighth...
Everolimus in Advanced Neuroendocrine Tumors
On February 26, 2016, everolimus (Afinitor) was approved for treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable, locally advanced, or metastatic.1,2 The drug was previously approved for...
Study Supports an Immune Effect of Chemoradiation in Head and Neck Cancer
Definitive radiation, with or without chemotherapy, induces a combination of immune-stimulating and inhibitory effects in patients with squamous cell carcinoma of the head and neck, according to research presented by Jonathan Schoenfeld, MD, MPhil, MPH, at the 2016 Multidisciplinary Head and Neck...
Phone Triage System Offers Potential to Reduce Patient Visits to the Emergency Department for Cancer Treatment–Related Symptoms
A quality improvement initiative to reduce the reliance of patients on visits to the emergency department for treatment of side effects related to cancer treatment was reported to be highly effective, according to early findings from a new study. 1 The strategy, involving a telephone triage...
Regulators Embrace Immunotherapy
The Cancer Drug Development Forum exists to provide, as the name implies, a meeting place to bring together academia, the pharmaceutical industry, and most important regulators for full and frank discussions to facilitate anticancer drug development. In the recent past, the Cancer Drug Development...
Anticoagulation in Patients With Cancer: Understanding the Complexities of Prophylaxis and Management
Venous thromboembolic events are more prevalent in patients with cancer than in persons without it. Cancer is associated with a high rate of venous thromboembolism recurrence, bleeding, requirement for long-term anticoagulation, and reduced quality of life. Moreover, thrombosis is the second most...
Chronic Lymphocytic Leukemia: The Golden Drug Only for Golden Agers?
As reviewed in this issue of The ASCO Post, Burger and colleagues recently reported findings of the RESONATE-2 trial of ibrutinib (Imbruvica) vs chlorambucil (Leukeran) as initial therapy for elderly patients with chronic lymphocytic leukemia (CLL).1 The study met its primary endpoint of...
SGO 2016: Advanced Ovarian Cancer Caused by Genetic Mutations Linked to Better PFS and OS Following Treatment Including Bevacizumab
Women with advanced ovarian cancer caused by genetic mutations—including in BRCA1 and BRCA2—lived significantly longer than those who did not have a mutation following treatment with a chemotherapy regimen that included bevacizumab (Avastin). According to a study, those with BRCA1 and a ...
Dietary Glycemic Index Linked to Lung Cancer Risk in Non-Hispanic White Populations
Consuming a diet with a high glycemic index was independently associated with an increased risk of developing lung cancer in non-Hispanic whites, according to a new epidemiologic study from The University of Texas MD Anderson Cancer Center. This research, published by Melkonian et al in Cancer...
Laboratory Study Explores How High-Fat Diet Influences the Development of Intestinal Tumors
A study published by Beyaz et al in Nature reveals how a high-fat diet makes the cells of the intestinal lining more likely to become cancerous. It joins a growing body of research that finds obesity and eating a high-fat, high-calorie diet are significant risk factors for many types of cancer....
Increasing the Dose of Obinutuzumab Monotherapy Raised the Response Rate
A randomized phase II study in symptomatic, untreated patients with chronic lymphocytic leukemia (CLL) found an increased overall response rate with obinutuzumab (Gazyva) at a 2,000 mg vs 1,000 dose. In addition, the “data demonstrate that obinutuzumab produces a higher response rate in...
Questions From Younger Patients About Colorectal Cancer Should Be Addressed Promptly
A study in Cancer1 finding an increasing rate of colorectal cancer among patients under the age of 50 should serve to raise awareness about the need for testing among those with “red-flag” symptoms and earlier screening for those at high risk, the study’s corresponding author, Samantha Hendren, MD, ...
‘Red-Flag’ Symptoms That Could Signal Colorectal Cancer in Patients Under 50 Years Old Should Be Taken Seriously
In clinical practice, Samantha Hendren, MD, MPH, has been “shocked by what a large proportion of patients we are seeing who are under 50 and presenting with colorectal cancer,” often with advanced disease due to delayed diagnosis. “And that is because patients and physicians don’t even think of...
Cancer MoonShot 2020 Announces the Formation of a National Pediatrics Consortium
Cancer MoonShot 2020 has announced the formation of the Pediatrics Consortium focused on bringing the promise of combined immunotherapy as the next-generation standard of cancer care to children diagnosed with the disease. With leadership at Phoenix Children’s Hospital helping to initiate this...
Selected Abstracts From 2015 ASH Annual Meeting: Part 3
Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on the topic of anticoagulation and the cancer patient. For other selected abstracts from this conference, see the December 25, 2015, and the...
Adding Targeted Therapy to Chemoimmunotherapy in Patients With Chronic Lymphocytic Leukemia: Questions as to Optimal Strategy Remain
The HELIOS study is an international phase III trial of bendamustine (Treanda) plus rituximab (Rituxan) in combination with ibrutinib (Imbruvica) vs placebo in patients with previously treated chronic lymphocytic leukemia. As reported by Chanan-Khan in The Lancet Oncology1 and reviewed in this...
Eribulin Mesylate in Advanced Liposarcoma Previously Treated With an Anthracycline
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 28, 2016, eribulin mesylate (Halaven) was approved for...
Hyperthermic Laser Surgery Disrupts Blood-Brain-Barrier in Glioblastoma, Opening Path for Chemotherapy
Neurosurgeons at Washington University School of Medicine in St. Louis used hyperthermic laser ablation to shrink tumors in patients with recurrent glioblastoma and noted a temporary disruption of the blood-brain barrier, thereby enabling them to deliver chemotherapy to the peritumoral region....
Conquer Cancer Foundation–Funded Research Published in High-Impact Journals
The Conquer Cancer Foundation of the American Society of Clinical Oncology (CCF) encourages grantees to share the results of their research to help advance progress against cancer. Publication in peer-reviewed journals is one of the most important ways for scientists to achieve recognition. That...
Advanced Imaging May Be Unnecessary for Many Women With Early Breast Cancer, but Rate of Such Testing Remains High
Up to 60% of the computed tomography (CT) scans, bone scans, and positron emission tomography (PET) scans performed for more than 29,000 Michigan women diagnosed with early breast cancer between 2008 and 2014 could not be medically justified based on retrospective record review, according to the...
Carfilzomib Plus Dexamethasone in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 21, 2016, carfilzomib (Kyprolis) was approved for use in ...
Two Forms of Radiosurgery for Brain Metastases Are Equally Effective
While two advanced radiosurgery approaches—Gamma Knife and RapidArc—offer different strengths, they are equally effective at eradicating cancer in the brain, say researchers at Sidney Kimmel Cancer Center at Jefferson. Their study, published by Liu et al in Frontiers in Oncology,...
Children With Leukemia From High-Poverty Areas More Likely to Suffer Early Relapse
Among children with acute lymphoblastic leukemia (ALL), the most common pediatric cancer, those who live in high-poverty areas are substantially more likely to suffer early relapse than other patients, despite having received the same treatment, according to new research from Dana-Farber/Boston...
Expert Point of View: Irvin M. Modlin, MD, Lisa Bodei, MD, and Eric Liu, MD
The ASCO Post interviewed Irvin M. Modlin, MD, Emeritus Professor of Gastroenterological Surgery, Yale University School of Medicine, regarding his thoughts on the NETTER-1 results and peptide receptor radionuclide therapies for neuroendocrine tumors. Dr. Modlin led the first study of a peptide...
Metabolic Phenotyping of Blood Plasma Allows for the Detection of Lung Cancer
Metabolic phenotyping of blood plasma by proton nuclear magnetic resonance (H-NMR) identified unique metabolic biomarkers specific to lung cancer patients and allowed for the accurate identification of a cohort of patients with early and late-stage lung cancer. These findings were published by...
Study Finds No Progression-Free Survival Benefit for Weekly Dose-Dense vs Every-3-Week Paclitaxel Plus Carboplatin in Ovarian Cancer
Weekly dose-dense paclitaxel did not provide a progression-free survival benefit over every-3-week paclitaxel in combination with carboplatin and with or without elective bevacizumab (Avastin) in patients with previously untreated ovarian cancer, according to the results of the phase III GOG-0262...
Breast Reconstruction Using Abdominal Tissue: Differences in Outcome With Four Techniques
In women undergoing breast reconstruction using autologous tissue, newer muscle-sparing abdominal flaps can reduce complications while improving some aspects of quality of life, according to a study by Macadem et al in Plastic and Reconstructive Surgery. Comparison of four types of abdominal flaps ...
2016 Quality Care Symposium: New Triage System Decreases Emergency Room Visits by Oncology Patients in Florida
A quality improvement initiative to reduce patients’ reliance on emergency room (ER) visits to treat cancer treatment side effects has shown to be highly effective, according to early findings from a new study. The strategy, involving a telephone triage service coupled with patient education, ...
2016 Quality Care Symposium: Study Suggests Many Women With Early Breast Cancer Receive Unnecessary Imaging Tests
A new study suggests that up to 60% of the computed tomography (CT) scans, bone scans, and positron-emission tomography (PET) scans performed for more than 29,000 Michigan women diagnosed with early breast cancer between 2008 and 2014 could not be medically justified based on retrospective record...
Eye Movement Affected in Some Former Childhood Cancer Patients
A study from Lund University in Sweden has shown that commonly used chemotherapy toxins impair the eyesight in childhood cancer survivors in a way that indicates an impact on the central nervous system. The results were published by Einarsson et al in PLOS One. It was not the former patients' ...
First-in-Class Drug ONC201 Shows Potential for Some Blood Cancers
ONC201, an investigational anticancer drug that triggers cell death in various tumor types, may have clinical potential for some blood cancers including mantle cell lymphoma and acute myeloid leukemia (AML), according to a recent clinical study. A research team led by Michael Andreeff, MD, PhD,...
Minimal Residual Disease Identified by NPM1 Mutation May Be Prognostic Marker for Poorer Outcome in Standard-Risk AML
In a study reported in The New England Journal of Medicine, Ivey et al found that a leukemia-specific marker consisting of a mutation in the gene encoding nucleophosmin (NPM1) can be used to identify minimal residual disease in peripheral blood in standard-risk acute myeloid leukemia (AML), with...
Mistletoe
The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...
